EYPT vs FATE

EyePoint, Inc. vs Fate Therapeutics, Inc. — Valuation Comparison 2026

EYPT

Biotechnology
EyePoint, Inc.
Quality
5.6
out of 10
Value Trap
12
SAFE
Price
$13.50
Last close
Models
9/13
Active
VS

FATE

Biotechnology
Fate Therapeutics, Inc.
Quality
5.5
out of 10
Value Trap
24
SAFE
Price
$2.63
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType EYPT Fair ValueEYPT Upside FATE Fair ValueFATE Upside
Bayesian DCF Intrinsic $4.03 -70.2% $0.62 -76.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.76 -86.9% $0.18 -88.1%
Dynamic NAV Asset-Based $4.13 -69.4% $2.75 +4.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EYPT vs FATE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EYPT vs FATE — Which Stock Is More Undervalued?

EYPT scores higher with a 5.6/10 quality rating vs FATE's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing EyePoint, Inc. (EYPT) and Fate Therapeutics, Inc. (FATE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EYPT currently trades at $13.50 with a QOC of 5.6/10, while FATE trades at $2.63 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).